DMTTF - Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics | Benzinga
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. Following their arrangement plan under the BC Business Corporations Act, and pursuant to the agreement’s terms, Small Pharma is now a wholly-owned subsidiary of Cybin.
On the arrangement’s completion, the Canada-headquartered company holds 100% of all issued and outstanding London-based firm's shares, in exchange for the issuance of 0.2409 Cybin shares for each Small Pharma share held.
See Also: Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business
Contracted legal and financial advisors were Gowling WLG LLP (Cybin,) and Aird & Berlis LLP and Jefferies International Ltd (Small Pharma.)
Cybin’s CEO Doug Drysdale says the transaction’s closing constitutes a significant milestone as it "firmly” establishes the company as "a leader in the psychedelics sector.”
With the industry’s "largest, most advanced and well-protected” deuterated DMT pipeline program plus topline efficacy data ...